FILSPARI is the only Dual Endothelin Angiotensin Receptor Antagonist ... 50% of maximum label dose and maximally tolerated angiotensin-converting enzyme (ACE) inhibitors or ARB therapy.

For the safety analysis, patients were included if they had undergone randomization, were without critical Good Clinical Practice violations, and had taken ≥1 dose ... angiotensin-converting enzyme; ...

In contrast, ARBs would be expected to inhibit the biologic effects of angiotensin II more completely than ACE inhibitors, since they block the pathway more distally at the level of the receptor ...

Currently, there is evidence supporting the use of either an angiotensin receptor blocker or an angiotensin-converting enzyme inhibitor in the primary-prevention context. However, in the secondary ...

Valsartan is an angiotensin receptor blocker (“ARB”) that prevents angiotensin II from binding to its receptor, thereby reducing the blood-vessel-constricting effects of angiotensin II ...

Use of HF medications at baseline was high, with 92% taking a beta-blocker; 80% taking an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker or angiotensin receptor-neprilysin ...

Amicus Therapeutics reported a larger-than-expected loss for Q1 2025, with earnings per share (EPS) at -$0.16, missing the forecast of -$0.02. The company’s revenue also fell short of ...

The compound blocks a receptor on certain defense cells, thus preventing a derailed immune response. The study findings have been published in the journal Signal Transduction and Targeted Therapy.

Baseline characteristics were broadly similar among the trial groups, although more participants with diabetes were assigned to the dose-adjustment group than to the other groups (Table 1).

The compound blocks a receptor on certain defense cells, thus preventing a derailed immune response. The study findings have been published in the journal Signal Transduction and Targeted Therapy.